Subasumstat, a first-in-class inhibitor of SUMO-activating enzyme, demonstrates dose-dependent target engagement and SUMOylation inhibition, leading to rapid activation of innate and adaptive immune responses in the dose escalation portion of a phase 1/2 clinical study

Autor:	Saggu, G., Stroopinsky, D., Arkadiusz Dudek, Olszanski, A. J., Juric, D., Dowlati, A., Vaishampayan, U., Assad, H., Rodon, J., Gibbs, J., Green, J., Du, Z., Rudicell, R., Kannan, K., Gharavi, R., Gomez-Pinillos, A., Fram, R. J., Berger, A., Sachsenmeier, K., Kasar, S.
Rok vydání:	2022
Předmět:	Cancer Research Oncology
Zdroj:	Web of Science
ISSN:	0959-8049
DOI:	10.1016/s0959-8049(22)01134-0
Databáze:	OpenAIRE
Externí odkaz:	https://explore.openaire.eu/search/publication?articleId=doi_dedup___::08ba93032aaff6491faf5c7b9fa4c5bf https://doi.org/10.1016/s0959-8049(22)01134-0 Zobrazit plný text záznamu Full Text from ScienceDirect